Dossier assessment
Lanadelumab (hereditary angioedema, 2 to < 12 years) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Lanadelumab (hereditary angioedema, 2 to < 12 years) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Lanadelumab (hereditary angioedema, 2 to < 12 years) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Children aged 2 to 11 years for routine prevention of recurrent attacks of hereditary angioedema
Added benefit not proven
Project details
- Project no.
- A23-135
- Commission
- Commission awarded on 14.12.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A23-135_en
Connected Projects
-
Dossier assessment
Lanadelumab (hereditary angioedema) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Lanadelumab - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed